Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
// Burhan Hassan 1 , Argun Akcakanat 2 , Takafumi Sangai 1 , Kurt W. Evans 2 , Farrell Adkins 1 , Agda Karina Eterovic 3 , Hao Zhao 4 , Ken Chen 4 , Huiqin Chen 5 , Kim-Anh Do 5 , Shelly M. Xie 1 , Ashley M. Holder 1 , Aung Naing 2 , Gordon B. Mills 3 and Funda Meric-Bernstam 1,2 1 Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 2 Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 3 Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 4 Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 5 Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX Correspondence: Funda Meric-Bernstam, email: // Keywords : mTOR, Akt, rapamycin, everolimus, breast cancer Received : June 10, 2014 Accepted : August 09, 2014 Published : August 10, 2014 Abstract We tested the antitumor efficacy of mTOR catalytic site inhibitor MLN0128 in models with intrinsic or acquired rapamycin-resistance. Cell lines that were intrinsically rapamycin-resistant as well as those that were intrinsically rapamycin-sensitive were sensitive to MLN0128 in vitro . MLN0128 inhibited both mTORC1 and mTORC2 signaling, with more robust inhibition of downstream 4E-BP1 phosphorylation and cap-dependent translation compared to rapamycin in vitro . Rapamycin-sensitive BT474 cell line acquired rapamycin resistance (BT474 RR) with prolonged rapamycin treatment in vitro . This cell line acquired an mTOR mutation (S2035F) in the FKBP12-rapamycin binding domain; mTORC1 signaling was not inhibited by rapalogs but was inhibited by MLN0128. In BT474 RR cells, MLN0128 had significantly higher growth inhibition compared to rapamycin in vitro and in vivo . Our results demonstrate that MLN0128 may be effective in tumors with intrinsic as well as acquired rapalog resistance. mTOR mutations are a mechanism of acquired resistance in vitro ; the clinical relevance of this observation needs to be further evaluated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104 · cited 1×
“A variety of acquired genomic alterations that confer resistance to targeted therapies have been described including acquired Bcr-Abl mutations in response to imatinib treatment [44], ras mutations with cetuximab [45], EGFR mutations [46, 47] MET amplification with EGFR inhibitors[48], and loss of HER2 with trastuzuma…”
Defining the role of mTOR in cancer
Guertin, D. A., & Sabatini, D. M. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.05.008 · Cited by 2,833
Sarbassov, D. D., Ali, S. M., Kim, D.-H., Guertin, D. A., Latek, R. R., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2004) · Current Biology · doi:10.1016/j.cub.2004.06.054 · Cited by 2,665
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561
Self-citationCOSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer
Forbes, S. A., Bindal, N., Bamford, S., Cole, C., Kok, C. Y., Beare, D., Jia, M., Shepherd, R., Leung, K., Menzies, A., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq929 · Cited by 2,278 · cited 3×
“To understand the potential functional consequence of detected variants, they were compared with dbSNP, COSMIC [50], and TCGA databases, and were annotated them using VEP [60], Annovar [61], SIFT [62], Polyphen [63], and Condel [64].”
KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer
Lièvre, A., Bachet, J.-B., Le Corre, D., Boige, V., Landi, B., Emile, J.-F., Côté, J.-F., Tomasic, G., Penna, C., Ducreux, M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0191 · Cited by 2,229 · cited 1×
“A variety of acquired genomic alterations that confer resistance to targeted therapies have been described including acquired Bcr-Abl mutations in response to imatinib treatment [44], ras mutations with cetuximab [45], EGFR mutations [46, 47] MET amplification with EGFR inhibitors[48], and loss of HER2 with trastuzuma…”
BackgroundRegulation of translation initiation by FRAP/mTOR
Gingras, A.-C., Raught, B., & Sonenberg, N. (2001) · Genes & Development · doi:10.1101/gad.887201 · Cited by 1,545 · cited 2×
“Phosphorylation of 4E-BP1 by mTORC1 leads to its dissociation from eIF4E, allowing binding of eIF4G at the same site, hence allowing translation initiation complex formation at the 5` end of mRNAs [27].”
BackgroundMethodChen, J., Zheng, X. F., Brown, E. J., & Schreiber, S. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.11.4947 · Cited by 556 · cited 2×
“However, an extensive study of serine at 2035 showed that substituting with aspartate, threonine, glutamine, and isoleucine abolished FKBP12-rapamycin binding, whereas conversion to alanine had a similar binding affinity compared to wild-type [33].”
BackgroundTremblay, F., Brûlé, S., Hee Um, S., Li, Y., Masuda, K., Roden, M., Sun, X. J., Krebs, M., Polakiewicz, R. D., Thomas, G., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706517104 · Cited by 465 · cited 1×
“Activated S6K causes feedback inhibition of insulin-like growth factor-1 (IGF-1)/insulin signaling by phosphorylating insulin receptor substrate 1 (IRS-1) resulting in its degradation [10].”
BackgroundMittendorf, E. A., Wu, Y., Scaltriti, M., Meric-Bernstam, F., Hunt, K. K., Dawood, S., Esteva, F. J., Buzdar, A. U., Chen, H., Eksambi, S., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1735 · Cited by 330 · cited 1×
“A variety of acquired genomic alterations that confer resistance to targeted therapies have been described including acquired Bcr-Abl mutations in response to imatinib treatment [44], ras mutations with cetuximab [45], EGFR mutations [46, 47] MET amplification with EGFR inhibitors[48], and loss of HER2 with trastuzuma…”
BackgroundSelf-citation
Cited by
PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside
Alzahrani, A. S. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.07.009 · Cited by 1,054
Panwar, V., Singh, A., Bhatt, M., Tonk, R. K., Azizov, S., Raza, A. S., Sengupta, S., Kumar, D., & Garg, M. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01608-z · Cited by 967
“291 Pharma-ceutical companies and academic laboratories have developed numerous such inhibitors by exploiting the structure of the ATP binding pocket of kinases and the small ATP-competitive molecules.”
BackgroundTargeting mTOR for cancer therapy
Hua, H., Kong, Q., Zhang, H., Wang, J., Luo, T., & Jiang, Y. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0754-1 · Cited by 899
Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer
Yu, L., Wei, J., & Liu, P. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.06.019 · Cited by 763
Current treatment strategies for inhibiting mTOR in cancer
Chiarini, F., Evangelisti, C., McCubrey, J. A., & Martelli, A. M. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.11.004 · Cited by 275
Kim, J. H., Lee, C., Lee, M., Wang, H., Kim, K., Park, S. J., Yoon, I., Jang, J., Zhao, H., Kim, H. K., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00785-0 · Cited by 88
Self-citationTherapeutic Use of mTOR Inhibitors in Renal Diseases: Advances, Drawbacks, and Challenges
Viana, S. D., Reis, F., & Alves, R. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/3693625 · Cited by 48
“Remarkably, mTOR kinase inhibitors (TOR-KIs) were effective antiproliferators in cell models displaying insensitivity to the first-generation of mTOR inhibitors [46, 47].”
Background
Metadata
- Authors
- Hassan, B., Akcakanat, A., Sangai, T., Evans, K. W., Adkins, F., Eterovic, A. K., Zhao, H., Chen, K., Chen, H., Do, K.-A., Xie, S. M., Holder, A. M., Naing, A., Mills, G. B., & Meric-Bernstam, F.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2014-08-10
- Volume
- 5
- Issue
- 18
- Pages
- 8544-8557
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2119607485
- Cited by
- 61
- References
- 12
- FWCI
- 2.92
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.